Some tips on 226942-29-6

226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,226942-29-6

To a dry microwave vial under nitrogen was added 2,4-dichloro-6-methyl-l,3,5-triazine (150 mg, 0.915 mmol), 6-bromo-l,2,3,4-tetrahydroisoquinoline (195 mg, 0.919 mmol) and anhydrous NMP (2.5 mL). The reaction was flushed with nitrogen, then treated with triethylamine (400 mu, 2.87 mmol), capped and allowed to stir at room temp for 30 min. The reaction was then treated with morpholine (800 mg, 9.18 mmol) and stirred at room temp for 2 h. The resulting white solid was collected by vacuum filtration to afford 4-(4- (6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)-6-methyl-l,3,5-triazin-2-yl)mophiholine, 200 mg (54%). LCMS (M+l) = 390.1, 392.1. NMR (500 MHz, DMSO-de) delta 7.41 (d, J=1.7 Hz, 1H), 7.38 (dd, J=8.2, 2.1 Hz, 1H), 7.23 (d, J=8.2 Hz, 1H), 4.86 – 4.77 (m, 2H), 3.93 (br s, 2H), 3.78 – 3.69 (m, 4H), 3.62 (br d, J=4.6 Hz, 4H), 2.84 (br t, J=5.6 Hz, 2H), 2.20 (s, 3H).

226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem